TickerTalks
Browse all tickers →
TickerTalks›$NTRB
NTNTRB

Nutriband Inc.

$NTRB·$76M·Biotechnology·Healthcare
$6.22-0.8%YTD+44.9%1Y-19.2%
Price updated 21h ago·X counts updated 6d ago
NTNTRB
$NTRBNutriband Inc.
$6.22-0.80%42 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NTRB on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

42X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $NTRB's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 81% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NTRB — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Nutriband is a sub-$10 transdermal-pharma microcap at 5-year Nasdaq anniversary — niche pipeline, pre-revenue tape.

Nutriband is a specialty transdermal-drug-delivery platform whose 2026 story is pipeline validation and specifically addressing the opioid crisis — the CEO's featured appearance in Nick Shirley's opioid-crisis documentary is public-health credibility, not immediate commercial traction.

  • The P&L is literally pre-commercial: Q2 revenue was just $433K (down 35% YoY) at a -2,894% operating margin and EPS of -$0.10, with trailing EPS of $0 beat on tiny estimates — this is a company whose stock is driven by milestones and pipeline announcements, not quarterly fundamentals.
  • The specific capital-markets backdrop is unusual: 5-year Nasdaq anniversary plus the opioid-crisis documentary and the ARS Pharmaceuticals comparison article give the stock story-level validation but not operational commercial traction.

At 70% of its 52-week range and 74% above the 200-day going into Dec 7 earnings, the setup is a late-cycle hot-momentum coil on narrative. A specific commercial-partnership or FDA-pathway milestone is the trigger; another pre-revenue quarter without named commercial milestone keeps the chart stuck.

What to watch: Dec 7 Q2 earnings — any specific commercial-partnership, pipeline milestones, cash runway, and FDA-pathway commentary. Named partnership is the trigger; another all-milestone-only quarter is the invalidation.

On the calendar: 2026-12-07 — Q2 earnings

microcap pharmapre commercial

Read the AI verdict on $NTRB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Nutriband develops abuse-deterrent transdermal patches for opioids and other controlled substances to reduce medication misuse.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NTRB.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $NTRB

Neutral — Nutriband develops abuse-deterrent transdermal patches for opioids and other controlled substances to reduce medication misuse.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-131%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-453%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-7.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
31.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-113%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
28.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Sep 4, 2026$-0.07——
Q1 2026Jun 11, 2026$-0.10$-1.89+94.7%
Q1 2026Apr 29, 2026$-0.04$-1.89+97.9%
Q3 2025Dec 16, 2025$-0.12$-2.13+94.4%
Next earningsMon, Dec 7

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$433K-35.1%45.4%-289%$-0.10$-563K
Q4 FY25$401K-37.6%22.2%-255%$-0.08$-732K
Q3 FY25$346K-46.4%19.8%-1121%$-0.32$-1.8M
Q2 FY25$622K+40.6%25.2%-322%$-2.12$-1.3M

Forward consensus

3-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.7M$2.7M – $2.7M-$6.20-$6.20 – -$6.201
FY27$95.4M$95.4M – $95.4M$1.57$1.57 – $1.571
FY28$180.4M$180.4M – $180.4M$3.66$3.66 – $3.661

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.54%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+45.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 5.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.935-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 238-K — Item 7.01: Press release / Reg FD
AI summary

Nutriband Inc. (NTRB) announced via Reg FD on September 21, 2026 that its publicly traded warrants (Nasdaq: NTRBW) will expire at 5:00 p.m. Eastern Time on September 30, 2026 in accordance with their original terms; trading will cease at market close on September 30, after which any unexercised warrants will be voided and have no further value. Warrant holders must exercise before that deadline or forfeit their rights entirely. This is a material deadline event for existing warrant holders; post-expiration, those dilutive securities are permanently eliminated from the capital structure.

SC 13D/AActivist amendmentSep 15SC 13D/A
AI summary

Gareth Sheridan, CEO of Nutriband Inc. (NTRB), filed Amendment No. 1 to a Schedule 13D originally triggered in September 2021, reporting sole beneficial ownership of 1,786,000 common shares representing 14.2% of the class, funded from personal funds. The multi-year gap between the triggering event and this amendment reflects an administrative catch-up filing rather than a new transaction. As CEO, Sheridan's continued 14.2% stake aligns his economic incentives directly with shareholders.

8-KMaterial agreementJun 228-K — Item 1.01: Material agreement
+ 5 other (2 10-Qs · 2 10-Ks · 1 25-NSE) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274globenewswire.com·4d agoNutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technologyglobenewswire.com·9d agoNutriband Marks Five Years on Nasdaq – CEO Letter to Shareholdersglobenewswire.com·16d agoHead to Head Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)defenseworld.net·17d agoNutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisisglobenewswire.com·18d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $NTRB on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport